Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:52:17.196Z.
Calculation as of: 2026-10-06T17:52:17.196Z.
Quote observation: 2026-10-06T17:50:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a3d1fbdfc20658083391a22a35257b501cad1354629c31eed1b40f8a69f1a870
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Lucid Diagnostics Inc.
Market Cap
$113.89M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $113.89M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A |
| Genelux Corporation (GNLX)vs › | $114.57M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.94M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.17M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.51M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.41M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.31M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
